For the year ending 2025-12-31, LYRA had -$24,684K decrease in cash & cash equivalents over the period. -$28,975K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -28,919 |
| Stock-based compensation | 2,335 |
| Depreciation expense | 459 |
| Gain on sale of property and equipment | 8 |
| Prepaid expenses and other current assets | -2,069 |
| Operating lease right-of-use assets | -3,132 |
| Accounts payable | -516 |
| Accrued expenses and other current liabilities | -1,811 |
| Restructuring liability | -1,081 |
| Operating lease liabilities | -4,121 |
| Deferred revenue | -398 |
| Net cash used in operating activities | -28,859 |
| Purchases of property and equipment | 116 |
| Proceeds from the sale of property and equipment | 18 |
| Net cash (used in) provided by investing activities | -98 |
| Proceeds from sale of common stock, warrants and pre-funded warrants | 4,999 |
| Payment of deferred offering costs | 726 |
| Net cash provided by financing activities | 4,273 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -24,684 |
| Cash, cash equivalents and restricted cash, beginning of period | 42,570 |
| Cash, cash equivalents and restricted cash, end of period | 17,886 |
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)